Anavex Life Sciences Corp
NASDAQ:AVXL

Watchlist Manager
Anavex Life Sciences Corp Logo
Anavex Life Sciences Corp
NASDAQ:AVXL
Watchlist
Price: 3.95 USD 7.34%
Market Cap: 352.9m USD

Anavex Life Sciences Corp
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Anavex Life Sciences Corp
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Anavex Life Sciences Corp
NASDAQ:AVXL
Cash from Operating Activities
-$39m
CAGR 3-Years
-17%
CAGR 5-Years
-13%
CAGR 10-Years
-25%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Anavex Life Sciences Corp
Glance View

Market Cap
342.3m USD
Industry
Biotechnology

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 25 full-time employees. The company went IPO on 2006-04-13. The firm is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. The Company’s lead compound ANAVEX2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1066, and ANAVEX 1037. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066, a mixed sigma-1/sigma-2 ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer.

AVXL Intrinsic Value
38.14 USD
Undervaluation 90%
Intrinsic Value
Price

See Also

What is Anavex Life Sciences Corp's Cash from Operating Activities?
Cash from Operating Activities
-39m USD

Based on the financial report for Sep 30, 2025, Anavex Life Sciences Corp's Cash from Operating Activities amounts to -39m USD.

What is Anavex Life Sciences Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-25%

Over the last year, the Cash from Operating Activities growth was -27%. The average annual Cash from Operating Activities growth rates for Anavex Life Sciences Corp have been -17% over the past three years , -13% over the past five years , and -25% over the past ten years .

Back to Top